Table 2.
Periprocedural Complications of Catheter Ablation (A) and Adverse Events of Antiarrhythmic Drugs (B).
| A. Periprocedural Complications | ||||||||
|---|---|---|---|---|---|---|---|---|
| Study | Access Site Complications, n | Pericardial Effusion/tamponade, n | Esophageal Complications, n | Systemic Embolism, n | Pulmonary Stenosis, n | |||
| MacDonald et al., 2011 [23] | 0 | 2 | 0 | 0 | 0 | |||
| ARC-HF, 2013 [21] | 1 | 1 | 0 | 0 | 0 | |||
| CAMTAF, 2014 [20] | 0 | 1 | 0 | 1 | 0 | |||
| AATAC, 2016 [19] | 2 | 1 | 0 | 0 | 0 | |||
| CAMERA-MRI, 2017 [24] | 1 | 0 | 0 | 0 | 0 | |||
| CASTLE-AF, 2018 [18] | 3 | 3 | 0 | 0 | 1 | |||
| AMICA, 2019 [13] | 2 | 1 | 1 | 0 | 0 | |||
| CABANA, 2021 [17] | 15 | 2 | 4 | 0 | 0 | |||
| RAFT-AF, 2022 [14] | 9 | 6 | 1 | 4 | 0 | |||
| OVERALL, % | 2.37% | 0.8% | 0.07% | 0.01% | 0.001% | |||
| B. Antiarrhythmic Drug Adverse Events | ||||||||
| Study | Thyroid toxicity, n | Liver and Pulmonary toxicity, n | Proarrhythmic effect, n | Unspecified toxicity, n | ||||
| AATAC, 2016 [19] | 4 | 3 | ||||||
| CABANA, 2021 [17] | 9 | 2 | 3 | 5 | ||||
| RAFT-AF, 2022 [14] | 4 | 1 | ||||||
| OVERALL, % | 1.38% | 0.48% | 0.8% | 0.7% | ||||